Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,448 matching trials from the live ClinicalTrials.gov search.
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

NCT03197961
Conditions
HIV/AIDS, Contraception
Interventions
tenofovir/emtricitabine, DMPA
Combination Product · Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Advanced Solid Tumors or Lymphomas
Interventions
CA-170
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Sarasota, Florida + 7 more
Active, not recruiting Phase 1 Interventional

Study of PYX-106 in Solid Tumors

NCT05718557
Conditions
Solid Tumor
Interventions
PYX-106
Drug
Lead sponsor
Pyxis Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more
Conditions
Sphingomyelin Lipidosis
Interventions
Olipudase alfa
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

NCT03655301
Conditions
Healthy Volunteers
Interventions
Copanlisib (Aliqopa, BAY80-6946), Metformin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Conditions
Solid Tumors
Interventions
INCB186748, Cetuximab, GEMNabP, mFOLFIRINOX
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more
Conditions
Advanced Solid Tumors
Interventions
E6201
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Las Vegas, Nevada + 9 more
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
Interventions
Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Denver, Colorado • Atlanta, Georgia • Baltimore, Maryland + 6 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2060 in Healthy Participants (MK-2060-016)

NCT06582602
Conditions
Venous Thrombosis
Interventions
MK-2060, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, molecular diagnostic method, immunologic technique, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Sacramento, California
Conditions
Healthy
Interventions
TG-0054
Drug
Lead sponsor
GPCR Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Day to 18 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
18
States / cities
Little Rock, Arkansas • Orange, California • Hartford, Connecticut + 13 more
Conditions
Diabetic Macular Edema
Interventions
Teprotumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Beverly Hills, California • St. Petersburg, Florida • Omaha, Nebraska
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

NCT04952545
Conditions
Healthy
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
AZD7789
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 1 more
Conditions
Advanced Solid Tumor
Interventions
Lunresertib, RP-3500, Zedoresertib
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 12 more
Conditions
Malignant Solid Tumor
Interventions
SAR439459, Cemiplimab REGN2810
Biological · Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Fairway, Kansas • Boston, Massachusetts • Durham, North Carolina + 2 more
Conditions
Non-hodgkin Lymphoma
Interventions
MT-3724
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years to 101 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Whittier, California • Plantation, Florida • Chicago, Illinois + 2 more
Conditions
Rheumatoid Arthritis
Interventions
JNJ-67484703, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Anniston, Alabama • Orland Park, Illinois
Conditions
Healthy
Interventions
AZD1722, Omeprazole
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Healthy Volunteers
Interventions
E2025, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Completed Phase 2 Interventional Results available

Pharmacokinetics/Pharmacodynamics of Albiglutide

NCT01357889
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide (GSK716155)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Dothan, Alabama • Long Beach, California • Riverside, California + 25 more